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TransportAlthough D-lactate metabolism has been shown to occur in a variety of mitochondria, the metabolic
fate of D-lactate in cancer cells has never been investigated, as it is believed to be exported to the
extracellular phase. We show that mitochondria from both cancer (PC-3) and normal (PNT1A) pros-
tate cells can metabolize D-lactate in an energy competent manner. This is due to the mitochondrial
D-lactate dehydrogenase, a membrane ﬂavoprotein, the activity and protein level of which are
higher in PC-3 than in PNT1A cells, as detected by both kinetic and immunological analysis. D-Lac-
tate can enter prostate mitochondria and cause the export of newly synthesized malate in a carrier-
mediated manner, with the rate of malate efﬂux from mitochondria twofold higher in cancer.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction drial metabolism [10]. We found that mitochondria from bothThe methylglyoxal (MG) pathway, which provides D-lactate (D-
LAC) as ﬁnal product (see Scheme 1), is largely modiﬁed in cancer
cells, including prostate cells [1,2], with a special role played by the
glyoxalase systems in eliminating the cytotoxic MG mostly derived
from glycolysis [3]. At present D-LAC is considered to be released
from cancer cells [4]; however the occurrence of D-LAC metabolism
was shown in yeast [5], mammalian [6,7] and plant [8,9] mito-
chondria where the existence of the D-lactate dehydrogenase (D-
LDH) was demonstrated. Thus to investigate whether and how
the mitochondrial metabolism of D-LAC can occur in cancer cells,
we resorted to cultured androgen-insensitive prostate cancer
(PC-3) cells and to normal immortalized prostate (PNT1A) cells,
used as a control, already used to study L-lactate (L-LAC) mitochon-prostate cell lines metabolize D-LAC with ATP production. Accord-
ingly, the occurrence of the ﬂavoprotein D-LDH is shown which is
associated to the inner face of the inner mitochondrial membrane.
Moreover, D-LAC can both enter prostate mitochondria and cause
the efﬂux of newly synthesized malate (MAL) in a carrier-mediated
manner. Interestingly, increase in all the investigated processes
was found in PC-3 cells, this perhaps favoring cancer cell viability
and proliferation.
2. Materials and methods
All the compounds used were of the highest grade of purity; in
particular control was made of the purity of D-lactate (Sigma–Al-
drich, cod.: 71716) via ﬂuorimetric assay of contaminating L-lac-
tate (0.1%) [11].
Cells were grown and handled as described in [10].
2.1. Sample preparation
Mitochondrial membrane enriched fractions (MMEF) and cell
soluble fractions (CSF) were obtained from ultrasound-treated
cells, as in [11]. Digitonin-permeabilized PNT1A (pPNT1A) or PC-
3 (pPC-3) cells were obtained as in [11], with digitonin (0.01% w/
v) incubated for 5 min at room temperature.
Scheme 1. The metabolism of lactate isomers in normal and cancer prostate cells. The novel scenario of the lactate isomer metabolism is shown. For details see the text. Solid
lines refer to experimental data, dotted lines refer to proposals. Grey circles report D-LAC-dependent processes. The arrows ( ) refer to the increase in indicated processes
which occurs in PC-3 with respect to PNT1A cells. Abbreviations not included in the text: Ac-CoA, acetyl-CoA; e, electrons; IMM, inner mitochondrial membrane; IMS,
mitochondrial intermembrane space; LG, S-D-lactoyl-glutathione; OAA, oxaloacetate; OMM, outer mitochondrial membrane; PM, plasma membrane. Carriers: ANT, adenine
nucleotide translocator; CT, citrate translocator; L-, D-LAC/H+, L-, D-LAC/H+ symporters; D-LAC/MAL, D-LAC/MAL antiporter; MCT, monocarboxylate translocator; TC,
tricarboxylate carrier. Enzymes: GR, glutathione reductase; GS-SG/GSH, oxidized/reduced glutathione; c/mL-LDH, cytosolic/mitochondrial L-lactate dehydrogenase; MDH,
malate dehydrogenase; c/mME, cytosolic/mitochondrial malic enzyme; PDH, pyruvate dehydrogenase; PC, pyruvate carboxylase; Respiratory chain complexes: I, NADH
dehydrogenase; II, succinate dehydrogenase; Q, coenzyme Q; III, complex III; c, cytochrome c; IV, cytochrome oxidase; V, ATP synthase.
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Teﬂon Dounce Potter homogenizer (40 strokes at 4 C).
Mitochondria were isolated by differential centrifugation
as in [13], with the cytosolic fractions (CF) deriving from the ultra-
centrifugation of the last supernatant (105000g for 60 min, 4 C).
2.2. Western blotting
Western blot analysis was carried out as in [12]. Cytosolic frac-
tions were concentrated twofold using a SAVANT Speedvac con-
centrator. Rabbit polyclonal anti-D-LDH (H-195) was from Santa
Cruz Biotechnology, Inc., CA.
2.3. Measurement of oxygen consumption, mitochondrial membrane
potential (DW) generation
Oxygen consumption was measured in pPNT1A or pPC-3 cells
(1 mg protein each) suspended in 1 ml of respiration mediumconsisting of 210 mM mannitol, 70 mM sucrose, 0.1 mM EDTA,
20 mM Tris–HCl pH 7.5, 3 mM MgCl2, 5 mM KH2PO/K2HPO4 (pH
7.4), at 37 C, essentially as [10].
DW generation was measured in pPNT1A or pPC-3 cells (1 mg
protein each), following the ﬂuorescence change (kex/kem = 520/
570 nm) of safranin O (10 lM) dissolved in standard medium con-
sisting of 0.2 M sucrose, 10 mM KCl, 1 mM MgCl2 and 20 mM
HEPES–Tris (pH 7.5), at 37 C [6].
2.4. Measurement of mitochondrial ATP appearance rate
The rate of mitochondrial ATP appearance was detected
photometrically at 334 nm as in [11]. ADP (0.5 mM) was
added to pPNT1A or pPC-3 cells (0.3 mg protein each) in the
presence of glucose, 2.5 mM, hexokinase, 2 e.u., glucose
6-phosphate dehydrogenase, 1 e.u. and NADP+, 0.2 mM (ATP
detecting system) plus diadenosine pentaphosphate (Ap5A,
10 lM).
Fig. 1. D-LAC-dependent oxygen consumption (A), DW generation (B) and mitochondrial ATP appearance. (A) pPNT1A or pPC-3 were added with: D-LAC (10 mM), ADP
(1 mM), ROT (10 lM), oxalate (OXAL, 10 mM), succinate (SUCC, 5 mM), malonate (MALO, 10 mM). Numbers along curves are rates of oxygen consumption expressed as natO/
min mg protein. (B) DWwas measured in either pPNT1A or pPC-3 cells. At the arrows D-LAC (10 mM) and the uncoupler FCCP (1.25 lM/10 ll) were added. Where indicated
either AA (10 lM) or ROT (10 lM) were added before D-LAC. (C) The rate of mitochondrial ATP appearance was measured in either pPNT1A or pPC-3 cells incubated in the
presence of the ATP detecting system plus Ap5A. Where indicated no respiratory substrate (control, C), succinate (+SUCC, 5 mM) or D-lactate (+D-LAC, 10 mM) was added
before ADP (0.5 mM). In the bar graphs the mean rates ± S.E.M. of three independent experiments are shown. ⁄P < 0.01.
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reduction
D-LDH activity was checked photometrically (k = 600 nm): sam-
ples were incubated in 0.8 ml of respiration medium (pH 7.5)
in the presence of rotenone (ROT, 10 lM), potassium cyanide
(CN, 1 mM), decylubiquinone (0.1 mM) and dichloroindophenol
(DCIP, 50 lM), at 37 C [14]. Cyt c reduction was monitored photo-
metrically (k = 550 nm) in MMEF incubated in 0.8 ml of respiration
medium containing ROT (10 lM), CN (1 mM) and oxidized cyt c
(20 lM), at 37 C, essentially as in [14].
2.6. Measurement of the redox state of mitochondrial ﬂavin/pyridine
cofactors
Flavin/pyridine cofactor redox state was detected ﬂuorimetri-
cally (kex–em = 450–520 or 334–456 nm, respectively) in cell
homogenates (hPNT1A or hPC-3) incubated in 2 ml ofstandard medium, at 37 C [6]. ROT (10 lM), antimycin (AA,
10 lM), CN (1 mM) and FCCP (1.25 lM) were added before D-
LAC.
2.7. Detection of mitochondrial swelling
Mitochondria from PNT1A (PNT1A-M) or PC-3 (PC-3-M) cells
(0.1 mg protein each) were suspended in isotonic solutions of
either sucrose, ammonium phosphate (NH4-Pi), or ammonium D-
LAC (NH4-D-LAC) and the absorbance change was monitored at
546 nm, as in [6].
2.8. Malate efﬂux detection
Malate efﬂux from PNT1A-M or PC-3-M (0.1 mg protein each)
was detected photometrically (k = 334 nm) in the presence of
0.25 mM NADP+ plus 0.2 e.u. malic enzyme (malate detecting sys-
tem), at 25 C [6].
Fig. 2. D-LDH activity assay (A) and D-LAC-dependent cyt c (B) and ﬂavin (C) reduction. (A) D-LDH activity was monitored in CSF or MMEF from PNT1A (nCSF, nMMEF, 0.055
and 0.17 mg, respectively) or PC-3 (cCSF, cMMEF, 0.055 and 0.18 mg, respectively) cells. Where indicated D-LAC (5 mM) and OXAL (10 mM) were added. Numbers along
curves are rates expressed as nmol DCIP reduced/min mg protein. (B) Cyt c reduction was monitored in nMMEF or cMMEF (0.24 and 0.20 mg, respectively). At the arrows D-
LAC (10 mM) and AA (10 lM) were added. Numbers along curves are rates expressed as nmol cyt c reduced/min mg protein. (C) The change in the redox state of
mitochondrial ﬂavin, or pyridine cofactor (inset), was monitored ﬂuorimetrically in hPNT1A or hPC-3 cells (0.9 and 0.75 mg protein, respectively). At the arrow D-LAC
(10 mM) was added. Numbers along curves are rates of ﬂavin reduction expressed as a.u./min mg protein.
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3.1. D-Lactate is oxidized by both normal and cancer prostate cells in
an energy-competent manner
D-LAC metabolism in prostate cells was ﬁrst checked by using
either pPNT1A or pPC-3 in which mitochondria are still coupled
with a respiratory control index, i.e. the ratio of the rates of oxygen
consumption due to succinate (SUCC, 5 mM) addition in the pres-
ence and absence of ADP (1 mM), equal to 4.5 ± 1.0 in three sepa-
rate experiments. The addition of D-LAC (10 mM) to either
pPNT1A or pPC-3 (Fig. 1A) resulted in oxygen consumption at rates
of about 1 and 2 nat O/min mg protein; as a result of ADP addi-
tion (1 mM) the rates were about 5 and 9 nat O/min mg protein,
respectively. The mean rates of D-LAC-dependent oxygen con-
sumption stimulated by ADP, obtained from three separate exper-
iments, were 5.5 ± 0.7 and 9.3 ± 1.0 nat O/min mg protein in
pPNT1A and pPC-3 cells, respectively, statistically different fromone another (P < 0.01). In both cases oxygen consumption was
insensitive to the complex I inhibitor ROT (10 lM), but was abol-
ished by oxalate (OXAL, 10 mM), inhibitor of D-LDH [15] and by
AA (10 lM), inhibitor of complex III (not shown). The addition of
SUCC (5 mM) proved to restore oxygen consumption at rates of
about 40 nat O/min mg protein in both cases; oxygen consump-
tion was abolished by malonate (10 mM), inhibitor of succinate
dehydrogenase (Fig. 1A).
The ability of D-LAC to generate DW was checked: D-LAC
(10 mM) addition to either p-PNT1A or p-PC-3 caused DW genera-
tion at a higher rate and extent in the latter (Fig. 1B). D-LAC-depen-
dent DW generation was prevented by AA (10 lM), but not by ROT
(10 lM) (Fig. 1B). In both cell lines the addition of the uncoupler
FCCP (1.25 lM) abolished DW. Fig. 1A and B shows that D-LAC is
a respiratory substrate for prostate mitochondria and that its oxi-
dation is coupled to ATP production in both cell types. To conﬁrm
that D-LAC is an energy source for mitochondria we measured the
rate of ATP appearance outside mitochondria due to ADP (0.5 mM)
Fig. 3. Western blotting (A) and kinetic (B, C) analysis of D-LDH. (A) PNT1A and PC-3 cell lysates (a), lysed mitochondria (LM) and CF (100 lg) (b), MMEF and CSF fractions
(60 lg proteins) (c) were analyzed for D-LDH protein expression. Representative blottings from two independent experiments are shown. D-LDH protein levels were
normalized against CypD (in LM and MMEF) or tubulin (in CF and CSF). In the bar graphs the normalized D-LDH levels found in PNT1A samples were set as 100%. (B, C) D-LDH
activity was detected in MMEFs as in Fig. 2A. In (C) the pH was adjusted to the indicated values by either TRIS or HCl addition to the medium. D-LAC (20 mM) was added to
start D-LDH reaction. Means ± S.E.M. of three independent experiments are reported in the graphs. ⁄P < 0.01.
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trol) or presence of D-LAC (+D-LAC, 10 mM) or SUCC (+SUCC, 5 mM),
used as energy sources. In both cases a signiﬁcant increase in the
rate of ATP appearance was found in the presence of D-LAC with re-
spect to controls (Fig. 1C). Moreover, the mean rate of ATP appear-
ance found in pPC-3 + D-LAC was about 60% higher than that found
in pPNT1A + D-LAC cells, in good agreement with the higher oxygen
consumption and DW generation rate (Fig. 1A and B). Contrarily,
pPNT1A + SUCC and pPC-3 + SUCC cells did not differ signiﬁcantly
with respect to the rate of ATP production (Fig. 1C).
3.2. The occurrence, subcellular localization, protein level and kinetics
of D-LDH in normal and cancer prostate cells
A variety of samples obtained from PNT1A and PC-3 cells,
including intact and Triton X-100 (TX-100, 0.2%)-solubilized mito-
chondria, CF, CSF, containing the mitochondrial intermembrane
space and the matrix, and MMEF were checked with respect to
the D-LDH reaction. This was made by measuring the changes in
the absorbance of oxidized DCIP (Fig. 2A). The D-LDH reaction
proved to occur only in MMEFs obtained from both PNT1A (n-
MMEF) and PC-3 cells (c-MMEF), at rates equal to 6 and 8 nmol
DCIP reduced/min mg protein, respectively. In both cases OXAL(10 mM) proved to inhibit the reaction. Interestingly, in agreement
with [6], no signiﬁcant D-LDH activity was found in intact mito-
chondria, this showing that the enzyme is located on the inner face
of the inner mitochondrial membrane (not shown). The association
of D-LDH to the inner membrane was conﬁrmed by checking
whether cyt c reduction occurs following D-LAC oxidation
(Fig. 2B). Either n- or c-MMEFs, incubated in the presence of oxi-
dized cyt c (20 lM), ROT (10 lM) and CN (1 mM), were added
with D-LAC (10 mM): cyt c reduction occurred at rates of 5 and
3 nmol/min mg protein in c- and n-MMEF, respectively and
was prevented by AA (10 lM) (Fig. 2C) and by oxalate (10 mM)
(not shown).
In another set of experiments the redox state of intramitochon-
drial NAD(P)H and ﬂavins, was monitored ﬂuorimetrically (Fig. 2C).
As a result of D-LAC (10 mM) addition to cell homogenates,
ﬂavin, but not NAD(P)+ reduction occurred at rates of 0.7 and 1.0
arbitrary units (a.u.)/mg protein for PNT1A and PC-3 homogenates,
respectively. This shows that, as in rat liver mitochondria [6], D-
LDH is a ﬂavoenzyme [see also: http://www.uniprot.org/uniprot/
Q86WU2].
Finally the occurrence of D-LDH in prostate cells was conﬁrmed
by Western blot analysis carried out on PNT1A and PC-3 cell ly-
sates, lysed isolated mitochondria (LM), CFs, CSFs and MMEFs. As
Fig. 4. Swelling of PNT1A-M and PC-3-M in NH4-D-LAC solution (A) and D-LAC-dependent malate efﬂux (B). (A) PNT1A-M or PC-3-M were rapidly added to 1 ml of either
sucrose (0.25 M), NH4-Pi (0.1 M), or NH4-D-LAC (0.1 M) solutions. Where indicated MERS (100 lM) was present in NH4-D-LAC solution. (B) PNT1A-M or PC-3-M were
incubated in the presence of the malate detecting system, in the absence or presence of PHESUCC (10 mM). At the arrows D-LAC (5 mM) and AA (10 lM) were added.
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(Fig. 3Aa), LM (Fig. 3Ab) and MMEFs (Fig. 3Ac), but not in the CFs
(Fig. 3Ab) and CSFs (Fig. 3Ac) this conﬁrming that the enzyme is
associated to the mitochondrial membranes. To rule out any con-
tamination and to normalize D-LDH protein level in each sample,
cytochrome c oxidase subunit I and cyclophilin D were checked
as mitochondrial marker proteins, being tubulin the cytosolic mar-
ker protein.
The dependence of the rate of D-LAC oxidation on increasing D-
LAC concentrations was investigated in either n- or c-MMEF
(Fig. 3B). Saturation kinetics was found in both cases. The mean
Km and Vmax values were equal to 2.9 ± 0.23 and 3.0 ± 0.36 mM
and 8.9 ± 0.24 and 12.0 ± 0.37 nmol DCIP reduced/min mg pro-
tein in three separate experiments, respectively. As judged by a
statistical analysis Vmax, but not Km values were found to be signif-
icantly higher in PC-3 with respect to PNT1A cells (P < 0.01), this
conﬁrming the results obtained from the immunological analysis.
The pH proﬁles of D-LDH activity, obtained from three separate
experiments by using 20 mM D-LAC to start D-LDH reaction, were
found to be similar in PNT1A with respect to PC-3 MMEF, with
the pH optimum equal to 7.5 and the reaction rate halving at both
pH 6.5 and 8.5, in both cases (Fig. 3C). Since both the enzyme afﬁn-
ity for D-LAC (Km value) and the pH proﬁle of normal and cancer D-
LDH do not differ signiﬁcantly, we conclude that no protein mod-
iﬁcation occurs in cancer.
3.3. D-LAC can both enter normal and cancer prostate mitochondria
and cause the efﬂux of newly synthesized malate in a carrier-mediated
manner
Having established that D-LDH is located in the inner mitochon-
drial compartment, a question rises as to whether and how D-LAC
formed in the cytosol enters mitochondria. In a ﬁrst set of experi-
ments we found that mitochondria isolated from both PNT1A andPC-3 cells (PNT1A-M and PC-3-M, respectively) undergo spontane-
ous swelling when suspended in 0.1 M ammonium D-LAC (NH4-D-
LAC) and that the thiol reagent mersalyl (MERS, 100 lM), which
cannot enter mitochondria, strongly reduces both rate and extent
of swelling in both cases (Fig. 4A). This shows that D-LAC can be ta-
ken up by mitochondria via a carrier-mediated transport and that
thiol group/s is/are present in the D-LAC carrier/s. Interestingly the
swelling extent in NH4-D-LAC solutions was lower in PC-3-M than
in PNT1A-M, this suggesting a different permeability of the mito-
chondria from normal and cancer cells to D-LAC. As a control of
mitochondrial intactness we conﬁrmed that no signiﬁcant swelling
occurred in 0.25 M sucrose solutions, whereas a rapid mitochon-
drial swelling occurred in ammonium phosphate (NH4-Pi) isotonic
solutions (Fig. 4A).
Finally the ability of D-LAC (5 mM) to cause the efﬂux of reduc-
ing equivalents from mitochondria in the form of malate (MAL)
was checked photometrically. As a result of 5 mM D-LAC addition
to either PNT1A-M or PC-3-M, MAL appearance occurred at a rate
of 2.3 and 4.4 nmol nmol/min mg protein, respectively. This
was abolished in both cases by AA (10 lM). Phenylsuccinate
(PHESUCC), a non-penetrant compound which inhibits a variety
of carriers including the D-LAC/MAL antiporter [6,9], prevented D-
LAC-dependent MAL efﬂux (Fig. 4B), this showing that MAL efﬂux
likely in exchange with D-LAC, is a carrier mediated process.
4. Discussion
To date D-LAC, which is produced in the methylglyoxal pathway,
is assumed to be released by cancer cells [4]. This paper ﬁrst shows
that cancer cells, namely prostate PC-3 cells, can metabolize D-LAC
thus completing the mitochondrial scenario of the lactate isomers
(Scheme 1).
L-LAC and D-LAC can both enter prostate cells perhaps via a
monocarboxylate translocator [16] and be formed in the cytosol
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isomers can enter mitochondria in a carrier mediated manner,
probably via D-LAC/H+ and L-LAC/H+ symporters inhibited by MERS
[10]. L-LAC and D-LAC are oxidized inside prostate mitochondria by
two separate enzymes, namely the mL-LDH located in the matrix
[10] and the D-LDH, a ﬂavoprotein associated to the inner face of
the inner mitochondrial membrane, respectively. Similarly to what
found for L-LAC [10], the mitochondrial metabolism of D-LAC in
cancer cells is more active than in normal cells. Whether this is
due to the higher mL-LDH [10] and D-LDH expression and activity
in PC-3 cells (Fig. 3), or to a higher efﬁciency of cancer mitochon-
dria to take up lactate isomers from the cytosol (Fig. 4) remains
to be established.
Although we found that prostate mitochondria oxidize L-LAC
rather poorly [10], at present further investigations are required
to ascertain whether, as in HepG2 cells [17], L-LAC metabolism
does not result in energy production. Moreover L-LAC might have
a role as a signaling molecule (see [18]). Thus currently the com-
parison between D- and L-LAC metabolism must remain a matter
of speculation. Similarly to D-lactate, the mitochondrial metabo-
lism of L-LAC seems to account for citric cycle anaplerosis [10]. This
was conﬁrmed by initial experiments in which we found a signiﬁ-
cant increase in intramitochondrial citrate amount as a result of L-
LAC addition to PC-3-M (not shown).
D-LAC metabolism occurs in an energy competent manner in
both prostate cell lines (Figs. 1 and 2). Since both D-LAC-dependent
oxygen consumption and DW generation are not inhibited by ROT
and no detectable intramitochondrial NAD(P)H ﬂuorescence re-
sults from D-LAC metabolism, we conclude that either the newly
synthesized pyruvate (PYR) is not oxidized via pyruvate dehydro-
genase [17], or the newly synthesised NADH is quickly oxidized in-
side mitochondria; this remains to be established. Thus PYR is
assumed to produce MAL via pyruvate carboxylase plus malate
dehydrogenase and/or the mitochondrial malic enzyme [19];
MAL in turn exits mitochondria likely in exchange with further
D-LAC, perhaps via the D-LAC/MAL carrier, inhibited by PHESUCC
[6,9]. In the cytosol MAL can account for NADPH formation via
the cytosolic malic enzyme reaction. Thus the mitochondrial trans-
port and oxidation of D-LAC could both favor the elimination of the
toxic MG and contribute to reactive oxygen species scavenging and
fatty acid synthesis, all crucial for cancer cell viability and prolifer-
ation and requiring NADPH (Scheme 1). Accordingly, we found that
cytosolic NADP+-malic enzyme activity is about ﬁve fold higher in
PC-3 with respect to PNT1A cells (not shown).
Thus D-LAC metabolism could represent a novel target for the
development of anticancer therapeutic strategies.
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